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Objective: To investigate immunostimulatory effects of acetylsali-
cylic acid during experimental human endotoxemia and in sepsis 
patients.
Design: Double-blind, randomized, placebo-controlled study 
in healthy volunteers and ex vivo stimulation experiments using 
monocytes of septic patients.
Setting: Intensive care research unit of an university hospital.
Subjects: Thirty healthy male volunteers and four sepsis patients.
Interventions: Healthy volunteers were challenged IV with endo-
toxin twice, at a 1-week interval, with each challenge consisting of a 
bolus of 1 ng/kg followed by continuous administration of 1 ng/kg/hr 
during 3 hours. Volunteers were randomized to acetylsalicylic acid 
prophylaxis (80 mg acetylsalicylic acid daily for a 14-d period, 
starting 7 d before the first endotoxin challenge), acetylsalicylic 
acid treatment (80 mg acetylsalicylic acid daily for the 7-d period 
in-between both endotoxin challenges), or the control group (re-
ceiving placebo). Furthermore, monocytes of sepsis patients were 
incubated with acetylsalicylic acid preexposed platelets and were 
subsequently stimulated with endotoxin.
Measurements and Main Results: Acetylsalicylic acid prophylaxis 
enhanced plasma tumor necrosis factor-α concentrations upon the 
first endotoxin challenge by 50% compared with the control group 
(p = 0.02) but did not modulate cytokine responses during the 
second endotoxin challenge. In contrast, acetylsalicylic acid treat-
ment resulted in enhanced plasma levels of tumor necrosis factor-α 
(+53%; p = 0.02), interleukin-6 (+91%; p = 0.03), and interleukin-8 
(+42%; p = 0.02) upon the second challenge, whereas plasma levels 
of the key antiinflammatory cytokine interleukin-10 were attenuated 
(–40%; p = 0.003). This proinflammatory phenotype in the acetyl-
salicylic acid treatment group was accompanied by a decrease in 
urinary prostaglandin E metabolite levels (–27% ± 7%; p = 0.01). Ex 
vivo exposure of platelets to acetylsalicylic acid increased produc-
tion of tumor necrosis factor-α (+66%) and decreased production 
of interleukin-10 (–23%) by monocytes of sepsis patients.
Conclusions: Treatment, but not prophylaxis, with low-dose ace-
tylsalicylic acid, partially reverses endotoxin tolerance in humans 
in vivo by shifting response toward a proinflammatory phenotype. 
This acetylsalicylic acid–induced proinflammatory shift was also 
observed in septic monocytes, signifying that patients suffering 
from sepsis-induced immunoparalysis might benefit from initiating 
acetylsalicylic acid treatment. (Crit Care Med 2019; 47:508–516)
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Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (1). Despite decades of research, sepsis incidence is increas-
ing (2), the associated healthcare costs are enormous, and 
sepsis represents the leading cause of in-hospital mortality 
(3). The pathophysiology of sepsis is highly complex, as the 
host response between patients is variable and can comprise 
both hyperinflammatory and immunosuppressive phenotypes 
(4). The latter phenotype, often referred to as sepsis-induced 
immunoparalysis, is increasingly recognized as the overriding 
immune dysfunction in septic patients (5, 6). Sepsis-induced 
immunoparalysis is characterized by impaired innate and 
adaptive immune responses, including exhaustion and apop-
tosis of lymphocytes, diminished capacity of monocytes and 
macrophages to produce cytokines, and decreased HLA-DR 
expression on the cell surface of monocytes (5, 7, 8). This sup-
pressed immune function may contribute to adverse outcome, 
as the host is unable to control the primary infection, and is 
increasingly susceptible toward secondary infections (6, 9–13). 
As such, these patients might benefit from immune stimula-
tory therapy to restore host defence.
In several large observational studies, prehospital use of 
low-dose acetylsalicylic acid (ASA or aspirin) was associated 
with reduced mortality in patients admitted to the ICU with 
sepsis (14–21). The most recent meta-analysis performed in 
17,065 patients showed a 7% reduction (range, 2–12%) in 
mortality in patients taking aspirin prior to sepsis onset (22). A 
large randomized controlled trial (AspiriN To Inhibit SEPSIS 
[ANTISEPSIS]) is currently being conducted to evaluate the 
effect of prehospital ASA use on outcome in the sepsis popu-
lation (23).
Although it is often proposed that antiinflammatory prop-
erties of ASA may account for the observed beneficial effects, 
ASA has been shown to potentiate, not attenuate, leukocytic 
cytokine production. For instance, previous data of our group 
show that a short course of oral aspirin in volunteers increases 
ex vivo cytokine production capacity (24). Furthermore, a 
7-day treatment with low-dose ASA in healthy volunteers 
resulted in a more pronounced increase in plasma levels of 
proinflammatory cytokines tumor necrosis factor (TNF)-
α, interleukin (IL)-6, and IL-8 during experimental human 
endotoxemia (25). Although subjectively counterintuitive, 
these findings are to be expected considering the inhibitory 
impact of aspirin on prostaglandins, a known negative reg-
ulator of (proinflammatory) cytokine production (26, 27). 
This indicates that low-dose ASA exerts proinflammatory 
effects during systemic inflammation. As a consequence, ASA 
may alleviate sepsis-induced immunoparalysis, which could 
contribute to the improved survival found in the abovemen-
tioned observational studies. However, the effects of ASA on 
the development of immunoparalysis have hitherto not been 
investigated.
In the present study, we investigated whether a course of 
low-dose ASA can prevent or reverse immunoparalysis in 
humans in vivo. Similar to previous work of our group, we 
used repeated experimental human endotoxemia as a model 
for sepsis-induced immunoparalysis (28). We investigated 
whether ASA can prevent immunoparalysis by treating sub-
jects 7 days before the first challenge until the second endotoxin 
challenge. Also, ASA’s potential to reverse immunoparalysis was 
investigated by treating subjects after the first endotoxin chal-
lenge. Furthermore, we investigated whether this ASA-induced 
pathway is still amenable in monocytes of septic patients.
MATERIALS AND METHODS
Subjects
After approval of the local ethics committee (CMO Arnhem-
Nijmegen; reference no. NL57410.091.16 and 2016–2550), 
30 healthy male volunteers between 18–35 years old were 
recruited. All subjects gave written informed consent and 
medical history, physical examination, laboratory tests, and a 
12-leads electrocardiogram did not reveal any abnormalities. 
Smoking, medication use (in particular the use of cyclooxy-
genase [COX] inhibitors), previous participation in experi-
mental human endotoxemia, or signs of acute illness within 
3 weeks prior to the start of the study were exclusion criteria. 
All study procedures were performed in accordance with the 
declaration of Helsinki, including the latest revisions. The 
study was registered at ClinicalTrials.gov (NCT02922673). 
For ex vivo stimulation experiments, we obtained monocytes 
from four patients with sepsis according to the Sepsis-3 cri-
teria (1) and platelets from three healthy volunteers. These 
experiments were approved by the local ethics committee 
(CMO Arnhem-Nijmegen; reference number 2016–2923 and 
2010–104).
Endotoxemia Study Design
We performed a randomized, double-blind, placebo-con-
trolled study, of which the design is depicted in Figure 1. All 
subjects were challenged IV with endotoxin twice, on study 
days 7 and 14. The second challenge was used to quantify the 
extent of endotoxin tolerance. Study medication was pre-
scribed in two 7-day courses prior to both endotoxin challenges 
and was encapsulated to maintain the double-blinded design. 
Subjects were randomized to one of three groups (n = 10 per 
group). The ASA prophylaxis group received 80 mg ASA once 
daily starting 1 week prior to the first endotoxin challenge and 
continuing until the second endotoxin challenge. The ASA 
treatment group received placebo once daily in the week prior 
to the first endotoxin challenge and 80 mg ASA once daily in 
the week prior to the second endotoxin challenge. The control 
group received placebo in the weeks prior to both endotoxin 
challenges. In both the ASA prophylaxis and ASA treatment 
groups, the first ASA dose administered was a loading dose 
of 160 mg, consistent with our previous work (25) and clin-
ical use of ASA. Therapy compliance was verified by diaries, 
pill counts, and urinary 11-dehydro-thromboxane (TX) B
2
 
concentrations.
All additional study procedures, including ex vivo experi-
ments with monocytes of sepsis patients, and analysis methods 
are provided in the Supplemental Digital Content.
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RESULTS
Subject Characteristics
Baseline demographic characteristics of the study population 
are listed in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/CCM/E307) and reveal no 
significant differences between the three study groups. Apart 
from the well-known endotoxin-induced symptoms, no ad-
verse events occurred during the study. There were no base-
line differences in urinary 11-dehydro-TXB
2
 levels between 
groups (Fig. S1, Supplemental Digital Content 1, http://links.
lww.com/CCM/E307). Therapy compliance was 100%, as 
verified by diaries and pill counts and confirmed by urinary 
11-dehydro-TXB
2
 concentrations, which were greatly reduced 
in all ASA-treated subjects (before ASA: 184 ± 28, after ASA: 
41 ± 8 pg/mL/creat; p < 0.0001) (Fig. S1, Supplemental Digital 
Content 1, http://links.lww.com/CCM/E307).
Plasma Cytokines
The first endotoxin challenge resulted in a profound inflam-
matory response, illustrated by an increase in plasma levels of 
all cytokines (TNF-α, IL-6, IL-8, IL-10, and IL-1 receptor an-
tagonist [RA] are depicted in Fig. 2, and monocyte chemoat-
tractant protein [MCP]-1, macrophage inflammatory protein 
[MIP]-1α, and MIP-1β in Fig. S2, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/E307). Individual data of the 
area under the time-cytokine concentration curves are depicted 
in Figure S3 (Supplemental Digital Content 1, http://links.lww.
com/CCM/E307). Plasma levels of IL-1β, IL-4, and IL-13 were 
below the detection limit of the assay in the great majority of 
samples obtained on both endotoxemia days (data not shown). 
Prophylactic use of ASA enhanced plasma concentrations of 
TNF-α by 50% compared with the control group upon the first 
endotoxin challenge (p = 0.02) (Fig. 2A; and Fig. S3A, Supple-
mental Digital Content 1, http://links.lww.com/CCM/E307) 
but did not significantly affect the other cytokines measured. 
Following the second endotoxin challenge, the development 
of endotoxin tolerance was illustrated by a severely blunted 
plasma cytokine response upon the second endotoxin chal-
lenge in the control group (decrease in area under the time 
concentration curve of TNF-α: 58% ± 11%, p = 0.003) (Fig. 
2A); IL-6: 73% ± 11%; p = 0.004 (Fig. 2B); IL-8: 65% ± 10%, 
p = 0.003 (Fig. 2C); IL-10: 56% ± 11%; p = 0.0034 (Fig. 2D); 
IL-1RA: 54% ± 14%; p = 0.003 (Fig. 2E); MCP-1: 38% ± 11%; 
p = 0.007 (Fig. S2A, Supplemental Digital Content 1, http://
links.lww.com/CCM/E307); MIP-1α: 48% ± 5%; p = 0.001 
(Fig. S2B, Supplemental Digital Content 1, http://links.lww.
com/CCM/E307); MIP-1β: 55% ± 11%; p = 0.01 (Fig. S2C, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E307).  Prophylactic treatment with ASA did not significantly 
affect the development of endotoxin tolerance (Fig. 2; and Figs. 
S2 and S3, Supplemental Digital Content 1, http://links.lww.
com/CCM/E307). In the ASA treatment group, endotoxin tol-
erance was less pronounced, illustrated by significantly higher 
plasma levels of TNF-α (+53%, p = 0.02) (Fig. 2A; and Fig. S3A, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E307), IL-6 (+91%; p = 0.03) (Fig. 2B; and Fig. S3B, Supple-
mental Digital Content 1, http://links.lww.com/CCM/E307), 
and IL-8 (+42%; p = 0.02) (Fig. 2C; and Fig. S3C, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E307) upon the 
second endotoxin challenge compared with the control group. 
The shift toward a more proinflammatory phenotype in the 
treatment group was further exemplified by lower plasma lev-
els of the key antiinflammatory cytokine IL-10 compared with 
the control group (–40%; p = 0.003) (Fig. 2D; and Fig. S3D, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E307). No between-group differences were found upon the 
second endotoxin challenge for IL-1RA, MCP-1, MIP-1α, and 
MIP-1β (Fig. 2E; and Figs. S2 and S3E–H, Supplemental Dig-
ital Content 1, http://links.lww.com/CCM/E307).
Figure 1. Endotoxemia study design. Procedures on the day of the first and second endotoxin challenge are similar. ASA = acetylsalicylic acid, 
LPS = lipopolysaccharide.
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HLA-DR Expression on Monocytes
ASA prophylaxis did not affect mHLA-DR expression in the ab-
sence of systemic inflammation (Fig. 3A). The first endotoxin 
challenge expectedly resulted 
in decreased mHLA-DR ex-
pression in subjects not (yet) 
exposed to ASA (the control 
and treatment groups, p < 0.01 
and p < 0.001), whereas no sig-
nificant decrease was observed 
in the ASA prophylaxis group. 
The second endotoxin challenge 
resulted in significantly atten-
uated mHLA-DR expression 
levels in all groups (p < 0.001) 
(Fig. 3A).
PGE-M
We did not observe differences 
in baseline urinary prosta-
glandin E metabolite (PGE-M) 
levels between the three groups 
(data not shown). Endotox-
emia resulted in increased uri-
nary PGE-M concentrations 
in all groups upon both en-
dotoxin challenges, with peak 
levels observed in urine col-
lected during the first 3 hours 
after the start of endotoxin 
administration. Peak PGE-M 
levels did not differ upon the 
first and second challenge in 
the control and ASA prophy-
laxis groups (Fig. 3B). In the 
ASA treatment group, peak 
PGE-M concentrations were 
significantly attenuated upon 
the second challenge com-
pared with the first (–27% ± 
7%; p = 0.01) (Fig. 3B).
Oxidative Stress
Plasma levels of malondial-
dehyde, a product of lipid 
peroxidation due to oxidative 
stress, increased upon both 
endotoxemia days. Malo-
ndialdehyde concentrations 
did not differ between the 
first and second endotoxin 
challenges within any of the 
groups. Furthermore, no 
between-group differences 
were observed (Fig. 4).
Hematologic and Clinical Variables
Transient changes in hematologic variables were observed dur-
ing both challenges; however, changes were less outspoken 
A
B
C
D
E
Figure 2. Plasma levels of tumor necrosis factor (TNF)-α (A), interleukin (IL)-6 (B), IL-8 (C), IL-10 (D), and 
IL-1 receptor antagonist (RA) (E), upon the first and second endotoxin challenge. Cytokine concentrations over 
time are depicted as mean and sem. The gray area indicates the 3-hr endotoxin administration period. p values 
represent the interaction term of repeated measures two-way analysis of variance. ASA = acetylsalicylic acid.
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upon the second challenge. ASA prophylaxis or treatment did 
not affect endotoxin-induced changes in cell counts or differ-
entiation (Fig. S4, Supplemental Digital Content 1, http://links.
lww.com/CCM/E307). The first endotoxin challenge caused a 
profound increase in body temperature, symptoms, and heart 
rate and a decrease in mean arterial pressure (MAP) (Fig. S5, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E307). The presence of endotoxin tolerance was character-
ized by less pronounced effects on clinical variables upon the 
second challenge in the control group (peak body temperature 
of 39.3°C ± 0.3°C vs 38.1°C ± 0.2°C, peak symptom score of 
8 ± 1 vs 3 ± 1, peak heart rate of 102 ± 3 vs 91 ± 2 beats/min, and 
nadir MAP 69 ± 2 vs 75 ± 3 mm Hg, for the first and second en-
dotoxin challenge, respectively). There were no differences in 
vital variables between the ASA prophylaxis or ASA treatment 
and the control group upon both endotoxin challenges.
Ex Vivo Monocyte Stimulation Experiments
We previously showed that ASA potentiates monocytic TNF-
α production in healthy volunteers in a platelet-dependent 
manner (25). We set out to investigate whether these effects 
also apply to monocytes of sepsis patients. Patient character-
istics (n = 4) are listed in Supplementary Table 2 (Supple-
mental Digital Content 1, http://links.lww.com/CCM/E307). 
Three patients exhibited mHLA-DR levels less than 12,000 
antibodies/cell, consistent with immune suppression (29). 
Compared to coincubation with naive platelets, coincubation 
with ASA preexposed platelets resulted in enhanced produc-
tion of TNF-α (+66%, 1,365 pg/mL [333–2,744 pg/mL] vs 
2,272 pg/mL [453–3,800 pg/mL]; p = 0.02) by lipopolysac-
charide (LPS)-stimulated monocytes, whereas production of 
IL-10 was decreased (–23%, 363 pg/mL [100–400 pg/mL] vs 
281 pg/mL [70–347 pg/mL]; p < 0.001) (Fig. 5). Coincubation 
A B
Figure 3. A, Monocytic human leukocyte antigen-DR (mHLA-DR) expression before (baseline) and 6 hr after start of the first and second endotoxin 
challenge. B, Peak urinary prostaglandin E metabolite (PGE-M) concentrations upon the first and second endotoxin challenge. Data are depicted as 
bar (mean) and scatter plots. **p < 0.01 and ***p < 0.001 compared with baseline in A (calculated using repeated measures one-way analysis of vari-
ance with Dunnett’s post hoc tests). Data (B) were analyzed using paired Student’s t tests. ASA = acetylsalicylic acid, NS = non significant.
Figure 4. Oxidative stress expressed by plasma levels of malondialdehyde (MDA) upon the first and second endotoxin challenge. MDA concentrations over 
time are depicted as mean and sem. The inserts depict the individual area under the time concentration curves (AUC) data expressed as nmol × hr/mL. The 
gray area indicates the 3-hr endotoxin administration period. p values represent the interaction term of repeated measures two-way analysis of variance. 
ASA = acetylsalicylic acid.
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of monocytes with ASA alone (without platelets) did not affect 
LPS-stimulated cytokine production (data not shown).
DISCUSSION
In the current study, we show that continuous administration 
of endotoxin to healthy volunteers results in the development 
of profound endotoxin tolerance, exemplified by a severely 
blunted cytokine response, fewer symptoms, and less changes 
in vital variables upon the second endotoxin challenge 1 week 
later. Prophylaxis with a clinically relevant dose of ASA (80 mg) 
resulted in an augmented proinflammatory response upon 
the first challenge but did not prevent or otherwise modulate 
the development of endotoxin tolerance observed during the 
second challenge. Treatment with a 7-day course of low-dose 
ASA in between both endotoxin challenges resulted in partial 
reversal of endotoxin tolerance, exemplified by a more proin-
flammatory phenotype upon the second endotoxin challenge 
compared with the control group. These data confirm pre-
vious reports that ASA augments the innate immune response 
(24, 25, 30, 31) and demonstrate that ASA treatment partially 
reverses endotoxin tolerance in humans in vivo. Furthermore, 
our ex vivo results reveal that this pathway is still amenable in 
sepsis patients, as the ASA-induced proinflammatory shift was 
also observed in monocytes obtained from these patients.
ASA treatment resulted in a distinct shift toward a more 
proinflammatory phenotype upon the second endotoxin chal-
lenge, exemplified by enhanced plasma levels of proinflam-
matory cytokines TNF-α, IL-6, and IL-8 compared with the 
control group, whereas the antiinflammatory IL-10 response 
was further decreased. Levels of another antiinflammatory cy-
tokine, IL-1RA, did not reveal a pattern similar to IL-10 but 
were also not enhanced like the proinflammatory mediators. 
Interestingly, an imbalance in the IL-6/IL-10 ratio was shown 
to correlate with an increased risk toward secondary infections 
in sepsis patients, and this effect was already observed when 
levels of IL-6 and IL-10 deviated greater than 30–50% from the 
mean values obtained in sepsis patients (32). In our study, the 
ASA-induced changes in cytokine levels/production in healthy 
volunteers in vivo (TNF-α: +53%, IL-6: +91%, IL-8: +42%, 
and IL-10: –40%) and in septic patients ex vivo (TNF-α: +66% 
and IL-10: –23%) were in the same order of magnitude or 
greater. Therefore, it appears plausible that the observed ASA-
induced shifts are of clinical relevance.
Although the beneficial effects of ASA are most frequently 
attributed to its antiinflammatory properties, proinflammatory 
characteristics of ASA were demonstrated decades ago in vitro 
(24, 30, 31), but also more recently in vivo by our group (25). 
These ASA-mediated effects appear to be dose specific, as in 
vitro work has revealed that low ASA dosages enhance cytokine 
responses, whereas very high dosages inhibit cytokine produc-
tion (33). Low-dose ASA potently acetylates the constitutively 
active enzyme COX-1, thereby irreversibly inhibiting the conver-
sion of arachidonic acids into prostaglandins (34). In addition, 
we have previously shown that platelets are critically involved 
in ASA’s proinflammatory effects, as coincubation of monocytes 
of healthy volunteers with ASA preexposed platelets augmented 
monocytic LPS-stimulated TNF-α production, whereas incuba-
tion of monocytes with ASA alone did not exert any effects (25). 
In the current study, we show that this ASA-induced pathway is 
still amenable in monocytes of sepsis patients and confirm that 
this effect is platelet dependent, as incubation with solely ASA 
did not exert any effects on monocytic cytokine production. 
Others have shown that platelets exert antiinflammatory effects 
during sepsis via the COX-1- prostaglandin E (PGE
2
)-pathway 
(35), and it is well established that PGE
2
 inhibits the release of 
TNF-α and IL-6 (27, 36), whereas it stimulates production of 
IL-10 (26). In accordance, we previously demonstrated that 
addition of PGE
2
 attenuated the proinflammatory effects of ASA 
in a dose-dependent manner (25). The present work reveals that 
the endotoxin-induced increase in urinary PGE-M concentra-
tions (as a surrogate measure of in vivo systemic PGE
2
 synthesis) 
was significantly attenuated upon the second endotoxin chal-
lenge in the ASA-treatment group. Taken together, we hypothe-
size that the ASA-induced COX-1 inhibition results in decreased 
levels of PGE
2
 and thereby abrogates the suppressive effects on 
LPS-induced proinflammatory cytokine production, ultimately 
resulting in increased production of these mediators (27).
Beneficial effects of antiplatelet therapy, and in particular of 
ASA, in the context of sepsis have been extensively described 
(18, 20, 37). In a recent meta-analysis using propensity match-
ing, the use of low-dose ASA prior to sepsis onset was asso-
ciated with a 7% reduction in mortality (22). Similar results 
were found in a Bayesian network meta-analysis, where pre-
hospital use of ASA was associated with lower hospital mor-
tality in septic patients (38). In accordance with previous work 
of our group (25), the present study demonstrates that ASA 
prophylaxis enhances TNF-α response upon the first endo-
toxin challenge. However, we now show that ASA prophy-
laxis does not affect the development of endotoxin tolerance. 
This shift toward a more proinflammatory profile upon the 
initial challenge could nevertheless represent an explanation 
for the abovementioned beneficial effects observed in sepsis 
patients on prehospital low-dose ASA treatment, as a more po-
tent host response may enhance clearance of pathogens (39). 
A B
Figure 5. Production of tumor necrosis factor (TNF)-α (A) and interleukin 
(IL)-10 (B) by monocytes obtained from septic patients after ex vivo 24 hr 
stimulation with lipopolysaccharide. Differences in cytokine production of 
monocytes coincubated with ASA preexposed platelets (ASA+) and naive 
platelets (ASA–) were analyzed using paired Student’s t tests on log-
transformed data. ASA = acetylsalicylic acid.
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In addition, ASA did not result in increased oxidative stress, 
this might indicate that the ASA-induced shift toward a more 
proinflammatory phenotype does not come at the expense of 
increased collateral damage.
Unfortunately, most epidemiologic studies that have evalu-
ated the effects of prehospital (low-dose) ASA on sepsis out-
come merely assessed clinical variables. To the best of our 
knowledge, only one study assessed circulating cytokine lev-
els, and no effects of prehospital ASA use on host-response 
variables were observed (40). Clearly, assessment of ASA’s pu-
tative immunomodulatory effects from these retrospective pa-
tient data is difficult. Interpatient variability is extensive, and 
it could be argued that, due to an enhanced initial immune 
response, prehospital ASA use renders patients less vulnerable 
to develop a severe sepsis that requires hospitalization (41). 
Therefore, it would be interesting to investigate the effects of 
prehospital ASA use on sepsis susceptibility. Interestingly, a 
large randomized clinical trial (ANTISEPSIS) is currently un-
derway that will address this question (23).
The effects of ASA in this study were mainly exerted at cyto-
kine production capacity level, while other immune variables 
were less strongly affected. In line with previous data of our 
group (28), experimental endotoxemia resulted in decreased 
mHLA-DR expression. This effect was similar across all groups 
and during both endotoxin challenges, although it did not 
reach statistical significance in the ASA prophylaxis group 
upon the first endotoxin challenge, which might be another re-
flection of the enhanced proinflammatory profile observed in 
this group. Despite the fact that the effects of ASA on HLA-DR 
expression were relatively small, they could still be of clinical 
relevance, as an increase of 4.8% in HLA-DR expression was 
shown to be associated with improved survival in patients suf-
fering from severe sepsis (42).
The ASA-induced shift toward a more proinflammatory 
phenotype was not reflected in the assessed clinical variables. 
This is likely explained by the fact that cytokine levels do not 
directly correlate with clinical variables in the experimental 
human endotoxemia model, as we have shown before (43). 
Rather, there appears to be a threshold effect, in which clinical 
variables only show changes when cytokine responses are pro-
foundly altered (43).
This study has limitations which should be acknowl-
edged. First, only male subjects and patients were studied. 
Pertaining to the endotoxemia results, females were previ-
ously shown to mount a more pronounced proinflammatory 
immune response upon endotoxin challenge (44), meaning 
that including both sexes would result in more interindivid-
ual variation and impair statistical power of the study (44). 
Furthermore, fluctuating hormone levels during the men-
strual cycle are also known to influence immune variables 
(45, 46), which would further increase variation. This would 
necessitate a larger sample size, which is undesirable for the 
very labor- and cost-intensive endotoxemia studies. Despite 
the fact that there are no indications that the immunologic 
response to ASA is different between males and females, the 
use of only males limits the generalizability of our work. 
Second, only young subjects were studied, whereas ASA 
therapy is used mostly in the aged, and sepsis patients are 
usually older as well. Again, there is no reason to assume that 
the immunologic response to ASA is different in older sub-
jects, and our ex vivo experiments using monocytes of (also 
older) sepsis patients corroborate this. Third, it should be 
noted that endotoxin tolerance only partially resembles sep-
sis-induced immunoparalysis. For instance, in sepsis patients 
also profound adaptive immune system derangements, such 
as lymphocyte apoptosis and dysfunction occur (7, 47). 
Administration of an endotoxin mainly results in activation 
of the innate immune system; there is no antigen presenta-
tion and no classic adaptive response, nor profound lym-
phocyte dysfunction and/or apoptosis as observed in sepsis. 
Nevertheless, human endotoxemia is the only human model 
available that captures several important hallmarks of both 
sepsis and sepsis-induced immunoparalysis, and the only 
human model to study these conditions. Furthermore, al-
though our model mimics infection with Gram-negative bac-
teria, transcriptomic analyses have revealed that most sepsis 
response pathways are common and independent of pathogen 
or source of infection (48). Both the considerable overlap in 
signaling pathways downstream of pathogen-specific pattern 
recognition receptors and inflammation-induced transloca-
tion of endotoxin from the gut to the circulation may explain 
these common responses (49). This suggests that our find-
ings may also be relevant for infections with other pathogens. 
Fourth, it has been reported that the efficacy of low-dose ASA 
varies between patients according to their lean body mass 
(50). Whereas this is not relevant for our study results (body 
mass index was equally distributed among groups), it might 
be relevant for patients. Furthermore, a certain part of the 
population appears to be resistant to the antiplatelet aggrega-
tion effects of low-dose ASA (51); however, it remains to be 
determined whether this also applies to the proinflammatory 
effects of ASA.
CONCLUSIONS
Treatment, but not prophylaxis, with low-dose ASA partially 
reverses endotoxin tolerance in humans in vivo by causing a 
shift toward a more proinflammatory phenotype. This effect 
likely involves inhibition of PGE
2
. This ASA-induced shift to-
ward a proinflammatory phenotype is also observed in mono-
cytes of sepsis patients, which signifies that patients suffering 
from sepsis-induced immunoparalysis may benefit from initi-
ation of ASA treatment in the hospital. Although prophylaxis 
with ASA did not prevent the development of endotoxin tol-
erance, the ASA-associated survival benefits in observational 
studies might be related to an augmented proinflammatory re-
sponse in the early phase of sepsis, resulting in improved bac-
terial clearance of their primary infection. As such, the current 
study provides a potential explanation of the benefits of ASA 
use in sepsis patients. If the upcoming ANTISEPSIS trial (23) 
confirms the association between ASA use and survival ben-
efits once again, a prospective trial with ASA in sepsis patients 
is highly warranted.
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